Prevents malaria. ANDA 207494, held by Prinston. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 207494 (Doxycycline Hyclate), held by Prinston, was first approved by FDA on Nov 15, 2016, with 2 approved supplements and 0 published complete response letters.
Doxycycline hyclate delayed-release tablets are a tetracycline-class drug indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 15, 2016 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 150MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 200MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 50MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Rx |
| Sep 18, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 18, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 15, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters